Fig. 4. In vivo stability of intact TXCs. (A) Structure of 89Zr-αCD22/XTEN (radiolabeled) and αHer2/XTEN-vcMMAE6 conjugates used to evaluate in vivo stability. (B) SEC-based tracking of 89Zr-radiolabeled antibody or TXC isolated from mice 1 hour or 5 days after dosing. (C) Ex vivo potency-based assessment in Her2-positive SkBR3 cells of αHer2/XTEN-vcMMAE6 TXC isolated from mice 1 day after dosing in comparison to the input (pre-dosed) TXC.
